CVRx Q2 FY26 earnings call CVRX

CVRX is experiencing significant sales force productivity challenges, primarily concentrated in regions with high turnover and less tenured leadership. Approximately 60% of quota-carrying territory managers joined in the last 18 months, straining onboarding and training processes. This has led to slower productivity ramps and negative implant growth rates in affected regions, offsetting strong growth elsewhere. To address this, the company is refining hiring profiles, investing in extended onboarding and hands-on field mentorship, and creating new field-based roles (reimbursement, business management, VP-level leaders) to free up area sales directors for coaching. Senior leadership talent is also being redeployed, with the Chief Marketing Officer moving to a direct field support role.

A major headwind stems from a large Medicare Advantage payer, whose prior authorization approval rate fell below 30% after implementing AI-based tools and new denial tactics. This has made physicians hesitant to recommend Barostem therapy. CVRX is appealing every denial and citing the favorable Humana coverage policy (which resulted in >90% approval rates) in all prior authorizations and discussions with other payers. Overall, the 30-day Medicare Advantage prior authorization approval rate improved to 60% in Q2 FY26 from 44% in 2025. Traditional Medicare payment for the Barostem procedure is stable at approximately 96% across all administrative contractors, supported by the Category 1 code implemented in January. Proposed 2027 Outpatient Prospective Payment System (OPPS) rules continue to support Barostem at $45,000 per procedure, and the Inpatient Prospective Payment System (IPPS) rate increased from $43,000 to $45,000 effective October 1st.

Despite short-term challenges, CVRX remains confident in its focused playbook of targeting the right centers and building sustainable programs. Regions with stable, seasoned leadership are demonstrating strong double-digit growth, validating the strategy. The BENEFIT-HF trial is tracking ahead of internal expectations for center activations and patient enrollment. The company is also significantly increasing investment in real-world evidence (RWE) data sets, with first publications expected this fall. These RWE data could potentially support an expansion of Barostem's indication and label through the new FDA real-world evidence pathway, which management believes could be a viable regulatory path.

In May 2026, CVRX received a civil investigative demand from the U.S. Department of Justice related to certain sales and marketing practices. The company is fully cooperating with the investigation, as described in its 10-Q filing. This development adds a layer of regulatory scrutiny to the company's operations.

Total revenue for Q2 FY26 was $15.7 million, a 16% increase year-over-year. U.S. revenue grew 21% to $14.8 million, driven by heart failure business expansion, new sales territories, and increased awareness. Europe revenue decreased 31% to $0.9 million. Gross profit increased 20% to $13.7 million, with gross margin at 87%. R&D expenses rose to $3.1 million, while SG&A expenses increased slightly to $23.6 million. The net loss was $14 million, or $0.53 per share. Cash and cash equivalents stood at $64.6 million as of June 30, 2026, with management indicating at least 18 months of cash runway and $40 million undrawn from a debt facility.